Home  »  Stock   »  Gear up for the change! Aurinia Pharmaceuticals In...

Gear up for the change! Aurinia Pharmaceuticals Inc. (AUPH) has hit the volume of 2307500

Aurinia Pharmaceuticals Inc. (AUPH) is priced at $8.61 after the most recent trading session. At the very opening of the session, the stock price was $8.30 and reached a high price of $8.75, prior to closing the session it reached the value of $8.21. The stock touched a low price of $8.13.Recently in News on January 24, 2023, Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Application (No. 17/713,140) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids using eGFR as a method of pharmacodynamically dosing the product in patients with lupus nephritis. The newly allowed application provides patent coverage that supplements Aurinia’s existing U.S. Patent No. 10,286,036, which is listed in the Orange Book and claims an FDA-approved method of using LUPKYNIS. The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label. This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037. The Company intends to list this newly allowed patent in the Orange Book once issued. You can read further details here

Aurinia Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.55 on 01/13/23, with the lowest value was $5.31 for the same time period, recorded on 01/03/23.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Aurinia Pharmaceuticals Inc. (AUPH) full year performance was -49.51%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Aurinia Pharmaceuticals Inc. shares are logging -57.92% during the 52-week period from high price, and 111.67% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.07 and $20.48.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2307500 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Aurinia Pharmaceuticals Inc. (AUPH) recorded performance in the market was 90.05%, having the revenues showcasing 15.63% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.11B, as it employees total of 300 workers.

Market experts do have their say about Aurinia Pharmaceuticals Inc. (AUPH)

During the last month, 0 analysts gave the Aurinia Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.46, with a change in the price was noted +1.29. In a similar fashion, Aurinia Pharmaceuticals Inc. posted a movement of +17.46% for the period of last 100 days, recording 2,764,954 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AUPH is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of Aurinia Pharmaceuticals Inc. (AUPH)

Raw Stochastic average of Aurinia Pharmaceuticals Inc. in the period of last 50 days is set at 83.49%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 83.49%. In the last 20 days, the company’s Stochastic %K was 78.68% and its Stochastic %D was recorded 76.83%.

Bearing in mind the latest performance of Aurinia Pharmaceuticals Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 90.05%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -21.81%, alongside a downfall of -49.51% for the period of the last 12 months. The shares increased approximately by -4.98% in the 7-day charts and went down by 78.48% in the period of the last 30 days. Common stock shares were driven by 15.63% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts